Celularity Inc. CELU

CELU Company Overview

Celularity Inc. is a U.S.-based biotechnology company focused on the development of placental-derived allogeneic cell therapies, biomaterial products, and regenerative medicine technologies. The company operates primarily in the biotechnology, cellular therapeutics, and advanced biomaterials industries. Celularity’s core strategy centers on leveraging postpartum human placental tissue as a source for cellular therapies intended for oncology, infectious disease, degenerative conditions, and tissue repair applications. The company also develops and commercializes biomaterial products used in wound care, surgical applications, and regenerative medicine.

The company’s principal business lines include its Cell Therapy platform, which develops allogeneic natural killer (NK) cell, T-cell, and mesenchymal-like adherent stromal cell therapies, and its Biomaterial Products business, which markets placental-derived products for wound management and surgical use. Revenue has historically been derived from commercial biomaterial products, licensing arrangements, and collaborative activities, while its therapeutic pipeline remains in various stages of clinical development. Celularity originated from assets associated with Celgene and was later established as an independent entity before becoming publicly traded through a merger with a special purpose acquisition company in 2021.